LOBE.CN

Lobe Sciences Ltd.

Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it... Read More...

Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible n... Read More...

Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other init... Read More...

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd... Read More...

Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.’s Global Regulatory and Development Strategy and its Implementation

Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with ... Read More...

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R) Market in the United States

Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under th... Read More...

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment ExperienceVancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Krysalis VX Innovations Inc. ("Krysalis")... Read More...

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

Natural health products will be manufactured and packaged by HAVN LifeVancouver, British Columbia--(Newsfile Corp. - May 19, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce it has entered into a production and supply agreement (the "Agreement") on May 14, 2021 with HAVN Life Scienc... Read More...

Lobe Sciences Announces Changes to Board of Directors

Appointment of Michael Petter to the Board brings another seasoned board member with strong industry, capital markets and strategic planning expertise.Vancouver, British Columbia--(Newsfile Corp. - January 8, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Mi... Read More...

Lobe Sciences Announces Further Upsizing and Second Closing of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce, that due to strong investor demand, it has further upsized its previously announced non-brokered private placement of units (the "Units") from $2,700,000 to $3,445,847 (the "O... Read More...

Lobe Sciences Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it intends to raise up to Cdn$2,000,000 (the "Offering") through a non-brokered private placement of up to 20,000,000 units (the "Units") at a price of Cdn$0.10 per Unit... Read More...